Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/
Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023
Rigl should be VTGN (Today) one day.
Yeah. Should be good Q.
Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
What a shoot! Amazing.
The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?
Nice spike AH today.
acting wild atm, but still healthy.
quite the dip
red to green
red to green
Wonderful!
Expect Q4 filing this week?
Be seeing that. Lot of 1.95 transactions so far
Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
SP should be a lot higher since the Q4 revenue is more than double from last year...
Apparently insider buying reported on ST. Take it for what it’s worth.
RIGL news out
Just like ABQQ. Right?
Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
This is a $10.00 per share stock in the very near future - EASILY!!
I just bought in. Seems like a good run could come in the near future.
Consolidating nicely on Continuation from last week!
GIVE ME MY $2DOLLAS…YA BUM
Followers
|
47
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
608
|
Created
|
12/01/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |